Developer docs
API playgroundTry for free, no card

Search company profiles

Numerion Labs

Full company profile

uuid0000ba4

Namestring
Numerion Labs
Legal namestring
Numerion Labs, Inc.
Websiteurl
numerionlabs.ai
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Numerion Labs is an AI-native biotechnology company founded in 2012 and headquartered at 250 Sutter Street in San Francisco, California, with 11–50 employees and Delaware incorporation. The company develops a proprietary AI chemistry superplatform for discovering novel small molecule drug candidates, with a therapeutic focus on immune and inflammatory diseases. Its platform integrates three components: COSMOS, a universal chemistry foundation model for predicting drug function from chemical structure; APEX, a hyper-scalable enumerator that screens 10 billion virtual compounds in under 30 seconds and was co-developed with NVIDIA; and EXPO, expert optimization algorithms that increase the probability of converting novel binders into first- and best-in-class drug candidates. The company claims to operate in a chemical space 10,000 times larger than competitors with 10-billion-fold higher screening efficiency and 100x more efficient model optimization.

Short descriptiontext

Numerion Labs is an AI-native biotechnology company using a proprietary platform—COSMOS foundation model, APEX hyper-scalable enumerator, and EXPO optimization algorithms—to discover small molecule drug candidates in immune and inflammatory diseases for pharmaceutical partners and its own pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, small molecule therapeutics, computational chemistry, machine learning, pharmaceutical partnerships
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
AI Drug Discovery
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Discovery Partnerships and Licensing
TypeLicensing Royalties
Description

Numerion Labs operates through strategic partnerships with pharmaceutical companies, developing proprietary drug candidates through its AI superplatform for immune and inflammatory diseases. The company appears to be building its own pipeline while also pursuing partnership models typical of AI-native biotech companies.

numerionlabs.ai
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Numerion Labs develops and operates an AI superplatform for drug discovery that combines a universal chemistry foundation model (COSMOS), a hyper-scalable virtual compound enumerator (APEX), and expert optimization algorithms (EXPO) to identify novel, drug-like small molecule candidates. The platform powers internal drug programs in immune and inflammatory diseases and is offered to pharmaceutical and biotechnology partners through strategic discovery collaborations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 10 billion virtual compounds screened in under 30 seconds
+3 more records
Product overview1 text field

Numerion Labs offers a unified AI superplatform for drug discovery, consisting of three integrated components: COSMOS (Universal Chemistry Foundation Model), APEX (Hyper-scalable Enumerator), and EXPO (Expert Optimization Algorithms). This architecture enables the platform to explore vast chemical space with 10,000x larger chemistry operating domain, 10-billion-fold higher screening efficiency, and 100x more efficient model optimization. The superplatform powers drug programs focused on immune and inflammatory diseases, delivering first- and best-in-class potential small molecule drug candidates.

Product and service2 records
1AI Drug Hunting Platform
CategoryAI Drug Discovery Platform
Description

An AI-powered superplatform that explores vast chemical space to discover novel, drug-like molecules, integrating the COSMOS universal chemistry foundation model, the APEX hyper-scalable enumerator, and the EXPO expert optimization algorithms. It is offered to pharmaceutical and biotechnology partners to accelerate their small molecule drug discovery pipelines.

2Immune and Inflammatory Disease Programs
CategoryTherapeutic Pipeline / Drug Programs
Description

A pipeline of proprietary drug programs born from the AI superplatform, delivering first- and best-in-class potential in immune and inflammatory diseases. These programs constitute Numerion Labs' own therapeutic pipeline and form the basis for partnership and licensing deals with pharmaceutical companies.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-29
Description

Numerion Labs partnered with NVIDIA to develop and publish breakthrough AI research on ultra-fast screening of hyper-scalable virtual libraries. The APEX Protocol, developed with NVIDIA technology, enables exhaustive evaluation of 10 billion virtual compounds in under 30 seconds, representing a significant advancement in AI-driven drug discovery computational capabilities.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BenevolentAI uses AI for drug discovery and has a focused pipeline including immune/inflammatory indications, directly comparable to Numerion Labs' therapeutic-area focus and platform-driven approach.

TypeDirect peer
Description

XtalPi uses AI and large-scale computation for small-molecule drug discovery and crystal-structure prediction, with similar enterprise-pharma discovery partnerships, comparable to Numerion Labs' AI-superplatform approach.

TypeDirect peer
Description

Exscientia is an AI-native drug discovery company that has advanced multiple candidates into the clinic and signed large pharma collaborations, making it a benchmark for Numerion Labs' platform-to-pipeline trajectory.

4Atomwise
TypeDirect peer
Description

Atomwise uses AI (AtomNet) for structure-based small-molecule drug design and partners with pharma on discovery programs, directly comparable to Numerion Labs' AI platform approach and pharma-licensing business model.

TypeDirect peer
Description

Recursion combines high-throughput biology with AI/ML to discover small molecules across multiple therapeutic areas and has signed large pharma partnerships, making it a direct competitor for both platform deals and pipeline talent.

TypeOthers
Description

NVIDIA is both a strategic technology partner and an ecosystem enabler for AI drug discovery via its Clara/BioNeMo offerings, providing the compute stack Numerion Labs' APEX Protocol depends on and competing for the same pharma compute budgets.

TypeDirect peer
Description

Schrödinger combines physics-based computational chemistry with ML for small-molecule discovery and discovery services, overlapping with Numerion Labs' COSMOS/APEX/EXPO capabilities and pharma customer base.

8Isomorphic Labs
TypeDirect peer
Description

Isomorphic Labs (Alphabet/DeepMind) applies AlphaFold-derived AI to drug discovery and partners with pharma (Novartis, Eli Lilly), representing a well-capitalized, foundation-model-based competitor in the same space as Numerion Labs.

TypeDirect peer
Description

Insitro applies ML to disease modeling and small-molecule discovery and has signed multi-billion-dollar partnerships with pharma (e.g., Bristol Myers Squibb, Eli Lilly), comparable to Numerion Labs' enterprise pharma GTM.

10Iambic Therapeutics
TypeDirect peer
Description

Iambic (formerly Entasis) develops AI-driven small-molecule therapeutics with a foundation-model-based platform, very similar in technology stack and pharma-partnering model to Numerion Labs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Numerion Labs

AI Drug Discoverynumerionlabs.ai

Numerion Labs is an AI-native biotechnology company using a proprietary platform—COSMOS foundation model, APEX hyper-scalable enumerator, and EXPO optimization algorithms—to discover small molecule drug candidates in immune and inflammatory diseases for pharmaceutical partners and its own pipeline.

What Numerion Labs does

Numerion Labs is an AI-native biotechnology company founded in 2012 and headquartered at 250 Sutter Street in San Francisco, California, with 11–50 employees and Delaware incorporation. The company develops a proprietary AI chemistry superplatform for discovering novel small molecule drug candidates, with a therapeutic focus on immune and inflammatory diseases. Its platform integrates three components: COSMOS, a universal chemistry foundation model for predicting drug function from chemical structure; APEX, a hyper-scalable enumerator that screens 10 billion virtual compounds in under 30 seconds and was co-developed with NVIDIA; and EXPO, expert optimization algorithms that increase the probability of converting novel binders into first- and best-in-class drug candidates. The company claims to operate in a chemical space 10,000 times larger than competitors with 10-billion-fold higher screening efficiency and 100x more efficient model optimization.

Numerion Labs firmographics

Firmographics
Name
Numerion Labs
Legal name
Numerion Labs, Inc.
Website
https://numerionlabs.ai
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Numerion Labs is an AI-native biotechnology company using a proprietary platform—COSMOS foundation model, APEX hyper-scalable enumerator, and EXPO optimization algorithms—to discover small molecule drug candidates in immune and inflammatory diseases for pharmaceutical partners and its own pipeline.
Ownership category
akta.pro rank

Numerion Labs industry classification

Industry
Product category
AI Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Small molecule therapeutics
  • Computational chemistry
  • Machine learning
  • Pharmaceutical partnerships

Where Numerion Labs is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Numerion Labs business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Drug Discovery Partnerships and Licensing: Numerion Labs operates through strategic partnerships with pharmaceutical companies, developing proprietary drug candidates through its AI superplatform for immune and inflammatory diseases. The company appears to be building its own pipeline while also pursuing partnership models typical of AI-native biotech companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Numerion Labs product offering

Product offering

Core offering

Numerion Labs develops and operates an AI superplatform for drug discovery that combines a universal chemistry foundation model (COSMOS), a hyper-scalable virtual compound enumerator (APEX), and expert optimization algorithms (EXPO) to identify novel, drug-like small molecule candidates. The platform powers internal drug programs in immune and inflammatory diseases and is offered to pharmaceutical and biotechnology partners through strategic discovery collaborations.

Product overview

Numerion Labs offers a unified AI superplatform for drug discovery, consisting of three integrated components: COSMOS (Universal Chemistry Foundation Model), APEX (Hyper-scalable Enumerator), and EXPO (Expert Optimization Algorithms). This architecture enables the platform to explore vast chemical space with 10,000x larger chemistry operating domain, 10-billion-fold higher screening efficiency, and 100x more efficient model optimization. The superplatform powers drug programs focused on immune and inflammatory diseases, delivering first- and best-in-class potential small molecule drug candidates.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI Drug Hunting Platform An AI-powered superplatform that explores vast chemical space to discover novel, drug-like molecules, integrating the COSMOS universal chemistry foundation model, the APEX hyper-scalable enumerator, and the EXPO expert optimization algorithms. It is offered to pharmaceutical and biotechnology partners to accelerate their small molecule drug discovery pipelines.
  • Immune and Inflammatory Disease Programs A pipeline of proprietary drug programs born from the AI superplatform, delivering first- and best-in-class potential in immune and inflammatory diseases. These programs constitute Numerion Labs' own therapeutic pipeline and form the basis for partnership and licensing deals with pharmaceutical companies.

Quantifiable outcome

  • 10 billion virtual compounds screened in under 30 seconds
  • +3 more outcomes

Companies that use Numerion Labs

Customer profile

Segments1 record

Ideal customer profiles1 record

Numerion Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature3 records

Numerion Labs partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NVIDIAcoreTechnology or Integration · 29 October 2025Numerion Labs partnered with NVIDIA to develop and publish breakthrough AI research on ultra-fast screening of hyper-scalable virtual libraries. The APEX Protocol, developed with NVIDIA technology, enables exhaustive evaluation of 10 billion virtual compounds in under 30 seconds, representing a significant advancement in AI-driven drug discovery computational capabilities.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Numerion Labs competitors and assessment

Company assessment

Direct peers

  • BenevolentAI: BenevolentAI uses AI for drug discovery and has a focused pipeline including immune/inflammatory indications, directly comparable to Numerion Labs' therapeutic-area focus and platform-driven approach.
  • XtalPi: XtalPi uses AI and large-scale computation for small-molecule drug discovery and crystal-structure prediction, with similar enterprise-pharma discovery partnerships, comparable to Numerion Labs' AI-superplatform approach.
  • Exscientia: Exscientia is an AI-native drug discovery company that has advanced multiple candidates into the clinic and signed large pharma collaborations, making it a benchmark for Numerion Labs' platform-to-pipeline trajectory.
  • Atomwise: Atomwise uses AI (AtomNet) for structure-based small-molecule drug design and partners with pharma on discovery programs, directly comparable to Numerion Labs' AI platform approach and pharma-licensing business model.
  • Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML to discover small molecules across multiple therapeutic areas and has signed large pharma partnerships, making it a direct competitor for both platform deals and pipeline talent.
  • Schrödinger: Schrödinger combines physics-based computational chemistry with ML for small-molecule discovery and discovery services, overlapping with Numerion Labs' COSMOS/APEX/EXPO capabilities and pharma customer base.
  • Isomorphic Labs: Isomorphic Labs (Alphabet/DeepMind) applies AlphaFold-derived AI to drug discovery and partners with pharma (Novartis, Eli Lilly), representing a well-capitalized, foundation-model-based competitor in the same space as Numerion Labs.
  • Insitro: Insitro applies ML to disease modeling and small-molecule discovery and has signed multi-billion-dollar partnerships with pharma (e.g., Bristol Myers Squibb, Eli Lilly), comparable to Numerion Labs' enterprise pharma GTM.
  • Iambic Therapeutics: Iambic (formerly Entasis) develops AI-driven small-molecule therapeutics with a foundation-model-based platform, very similar in technology stack and pharma-partnering model to Numerion Labs.

Others

  • NVIDIA (BioNeMo / Clara): NVIDIA is both a strategic technology partner and an ecosystem enabler for AI drug discovery via its Clara/BioNeMo offerings, providing the compute stack Numerion Labs' APEX Protocol depends on and competing for the same pharma compute budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Numerion Labs social profiles

Digital presence

Numerion Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Numerion Labs leadership team

Management profile

Number of profiles

Profiles1 record

Numerion Labs funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Numerion Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Numerion Labs

What does Numerion Labs do?

Numerion Labs develops and operates an AI superplatform for drug discovery that combines a universal chemistry foundation model (COSMOS), a hyper-scalable virtual compound enumerator (APEX), and expert optimization algorithms (EXPO) to identify novel, drug-like small molecule candidates. The platform powers internal drug programs in immune and inflammatory diseases and is offered to pharmaceutical and biotechnology partners through strategic discovery collaborations.

Is Numerion Labs a public or private company?

Numerion Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Numerion Labs founded?

Numerion Labs was founded in 2012. It employs 11 to 50 people.

Where is Numerion Labs based?

Numerion Labs is headquartered in San Francisco, United States, in the North America region.

How does Numerion Labs make money?

One revenue line is on record: drug Discovery Partnerships and Licensing.

Who are Numerion Labs's main competitors?

Direct peers on record are BenevolentAI, XtalPi, Exscientia, Atomwise, Recursion Pharmaceuticals, Schrödinger, Isomorphic Labs, Insitro and Iambic Therapeutics. NVIDIA (BioNeMo / Clara) is listed as an others.

Does Numerion Labs have an API?

No public API is recorded for Numerion Labs.

What industry is Numerion Labs in?

Numerion Labs's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CapgeminiRewiring early drug development with AI and digitalizationAI and digitalization are reshaping early-stage drug discovery, accelerating timelines by 20-50% and cutting costs by up to 50%. The article outlines six phases, including virtual screening and automated IND preparation, with examples like Numerion Labs screening 10 billion molecules in two days.HolidaylandmarkTop 10 Drug Discovery Platforms: Features, Pros, Cons & Comparison – Holiday LandmarkThe article presents a comparative analysis of the top 10 drug discovery platforms, evaluating tools from companies such as Schrödinger, Biovia, Atomwise, and Insilico Medicine based on features, pricing, and capabilities. It outlines key industry trends including AI-driven predictive modeling, multi-omics integration, and cloud-native deployment options to assist researchers in selecting appropriate software for their R&D pipelines.SecSEC FORM DNumerion Labs, Inc., a San Francisco-based biotechnology company incorporated in Delaware, filed a Form D notice with the SEC for an exempt offering of securities under Rule 506(b), seeking to raise up to $35 million through the sale of Series D Preferred Stock and Common Stock. The filing, signed by CEO Stephen Worland on March 19, 2026, discloses that $19,794,945 had already been sold as of the first sale date of March 10, 2026, with $15,205,055 remaining and five investors participating.openPR.comAI Drug Discovery Market Is Going to Boom | Major Giants Insilico Medicine, BenevolentAI, Exscientia, AtomwiseHTF Market Intelligence released a study forecasting the global AI Drug Discovery market through 2033, highlighting growth driven by rising R&D costs and advancements in generative AI. The report identifies key industry players including Insilico Medicine, BenevolentAI, Exscientia, Atomwise, and major pharmaceutical firms such as Pfizer and Roche. North America is noted as the dominant region, while Asia-Pacific is identified as the fastest-growing segment.HealthydataAtomwise vs Alternatives: Competitive Positioning for AI in Healthcare BuyersA buyer-grade guide compares Atomwise with BenevolentAI, Schrödinger, Exscientia, and Insilico Medicine, focusing on risk, credibility, and deal dynamics. It highlights integration, political safety, and scientific transparency as key evaluation areas for pharma and biotech leaders.Harvard Business SchoolAtomwise: Strategic Opportunities in AI for PharmaThe article presents a case study on Atomwise, co-founded by Abraham Heifets and Izhar Wallach, which developed an AI engine using convolutional neural networks to accelerate drug discovery. It outlines the strategic dilemma facing the founders in choosing between licensing their technology to pharmaceutical companies or operating as an independent pharmaceutical entity. The text highlights the divergent business paths available to leverage their computational chemistry tools for patient and investor value.openPR.comAI in Drug Discovery Market is projected to reach USD 11.47 billion by 2034Exactitude Consultancy projects the global AI in Drug Discovery market will grow from USD 1.92 billion in 2024 to USD 11.47 billion by 2034, representing a 19.4% compound annual growth rate. This expansion is driven by the integration of generative AI, increasing partnerships between pharmaceutical companies and AI startups, and advancements in precision medicine. Key industry players such as Insilico Medicine, Atomwise, and DeepMind are positioned to lead this transformation in biopharmaceutical R&D.AcquinoxAI-Driven Drug Discovery: Strategic InsightsThe article analyzes the strategic growth of the AI-driven drug discovery market, which was valued at approximately $1.7 billion in 2023 and is projected to expand at a compound annual growth rate of 29.7% through 2030. It highlights key private players such as Xaira Therapeutics, Insitro, and Atomwise that are leveraging machine learning to accelerate drug development and reduce costs. The report also outlines significant risks including data quality issues and regulatory challenges from agencies like the FDA and EMA.Martinimartini.ai ResearchSchrödinger, Inc. reported third-quarter 2025 revenue of $54.3 million, reflecting a 54% year-over-year increase driven by software licensing growth, while maintaining a net loss due to ongoing R&D investments. Despite this financial performance, the company's credit spread widened by 0.609 in the last month, signaling deteriorating credit quality and negative market sentiment relative to peers like Atomwise. Schrödinger maintains a strong liquidity position with cash exceeding debt, but faces volatility in its default probability and competitive pressures within the computational drug discovery sector.YahooAI to Revolutionize Pharma with 31.7% CAGR GrowthBCC Research released a report projecting the global market for artificial intelligence in pharmaceuticals to grow from $3.8 billion in 2025 to $15.2 billion by 2030, representing a compound annual growth rate of 31.7%. The study highlights that AI is accelerating drug discovery, optimizing clinical trials, and enabling precision medicine, with North America holding the largest market share at 59.5% in 2024. Key market leaders identified in the sector include companies such as NVIDIA Corp., Insilico Medicine, and Atomwise Inc.